Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan |
Shimizu, Hirotaka
(Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development)
Arai, Katsuhiro (Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development) Takeuchi, Ichiro (Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development) Minowa, Kei (Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development) Hosoi, Kenji (Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development) Sato, Masamichi (Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development) Oka, Itsuhiro (Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development) Kaburaki, Yoichiro (Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development) Shimizu, Toshiaki (Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine) |
1 | Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95; quiz e14-5. DOI |
2 | Hyams JS, Chan D, Adedokun OJ, Padgett L, Turner D, Griffiths A, et al. Subcutaneous golimumab in pediatric ulcerative colitis: pharmacokinetics and clinical benefit. Inflamm Bowel Dis 2017;23:2227-37. DOI |
3 | Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011;52:230-2. DOI |
4 | Courbette O, Aupiais C, Viala J, Hugot JP, Louveau B, Chatenoud L, et al. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2019;69:189-93. DOI |
5 | Naviglio S, Lacorte D, Lucafo M, Cifu A, Favretto D, Cuzzoni E, et al. Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study. J Pediatr Gastroenterol Nutr 2019;68:37-44. DOI |
6 | Birimberg-Schwartz L, Zucker DM, Akriv A, Cucchiara S, Cameron FL, Wilson DC, et al. Development and validation of diagnostic criteria for IBD subtypes including IBD-unclassified in children: a multicentre study from the pediatric IBD Porto group of ESPGHAN. J Crohn's Colitis 2017;11:1078-84. |
7 | Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-21. DOI |
8 | Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73; quiz 1165-6. DOI |
9 | Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32. DOI |
10 | Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010;105:1430-6. DOI |
11 | Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:391-9.e1. DOI |
12 | Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210-26. DOI |
13 | Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423-39. DOI |
14 | Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114-22. DOI |
15 | Takeuchi I, Kaburaki Y, Arai K, Shimizu H, Hirano Y, Nagata S, et al. Infliximab for very early-onset inflammatory bowel disease: a tertiary center experience in Japan. J Gastroenterol Hepatol 2020;35:593-600. DOI |
16 | Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. DOI |
17 | Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95. DOI |
18 | Cheng J, Hamilton Z, Smyth M, Barker C, Israel D, Jacobson K. Concomitant therapy with immunomodulator enhances infliximab durability in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2017;23:1762-73. DOI |
19 | Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2015;13:847-58.e4; quiz e48-50. DOI |